Feiyangchangweiyan capsule protects against ulcerative colitis in mice by modulating the OSM/OSMR pathway and improving gut microbiota

• Published in: Phytomedicine (Stuttgart) Vol. 80; p. 153372
• Main Authors: Li, Yao, Chen, Fei, Xie, Yanhua, Yang, Qian, Luo, Huanhuan, Jia, Pu, Shi, Zhihui, Wang, Siwang, Zheng, Xiaohui
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.01.2021
• Subjects: Animals; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Capsules; Chemokines - blood; Colitis, Ulcerative - chemically induced; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - microbiology; Colon - drug effects; Colon - metabolism; Colon - pathology; Colon - ultrastructure; Cytokines - blood; Dextran Sulfate - toxicity; Disease Models, Animal; Drugs, Chinese Herbal - pharmacology; Feiyangchangweiyan capsule; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - genetics; Intestinal flora; Male; Mice; Mice, Inbred C57BL; Oncostatin m; Oncostatin M - genetics; Oncostatin M - metabolism; Oncostatin M Receptor beta Subunit - genetics; Oncostatin M Receptor beta Subunit - metabolism; Protective Agents - pharmacology; Transcriptome sequencing; Ulcerative colitis; Pcoa; Il6st; Jnk; Nf-κb; Lda; Transcriptome sequencing; Ibd; Oncostatin m; Osmr; Mpo; Rda; Fyc; Ccl11; Feiyangchangweiyan capsule; Dss; Osm; Dai; Uc; Out; LEFSE; Mip; Fych; Intestinal flora; Mcp; Fycm; Fycl; Hplc; Ulcerative colitis
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2020.153372

Feiyangchangweiyan capsule (FYC) is a traditional Chinese medicine formulation used in the clinical treatment of acute and chronic gastroenteritis and bacterial dysentery. However, the effect of FYC on ulcerative colitis (UC) and the mechanism thereof remains unknown. To investigate the protective effect of FYC on UC mice induced by dextran sulfate sodium and illustrate the potential mechanism of this effect. Here, we established a model of UC mice by dextran sulfate sodium and administered with FYC. The disease activity index (DAI), colon length, myeloperoxidase (MPO) content in serum, pathological structure and ultrastructural changes, and inflammatory cell infiltration of colon tissue were evaluated. Transcriptome and 16S rDNA sequencing were employed to illuminate the mechanism of FYC in the protection of UC mice. FYC significantly alleviates the pathological damage and the infiltration of inflammatory cells in colon tissue of dextran sulfate sodium induced UC mice, rescues shortened colon length, reduces DAI score, MPO content in serum, and pro-inflammatory factors including IL-1β, IL-6, CCL11, MCP-1 and MIP-2, and increases anti-inflammatory factors such as IL-10. Transcriptomics revealed that Oncostatin M (OSM) and its receptor (OSMR) are the critical pathway for UC treatment by FYC. OSM and OSMR increased in UC mice compared to control mice, and decreased with FYC, which was verified via measurement of OSM and OSMR mRNA and protein levels. Furthermore, we observed that FYC modulates intestinal microbiome composition (e.g., the proportion of Barnesiella/Proteobacteria) by affecting the inflammatory factors. FYC exerts an effect on UC by inhibiting the OSM/OSMR pathway and regulating inflammatory factors to improve the intestinal flora. [Display omitted]